NDLI: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients

Content Provider	Springer Nature : BioMed Central
Author	Bi, Yazhen Wang, Zhaohui Feng, Saran Wang, Yan Zhao, Yang Li, Hong Yu, Jingyi Liu, Qian Zhu, Chuansheng Li, Mingzhuo
Abstract	Background Platelet counts varied over time after induction chemotherapy. We aimed to investigate the different trajectories of platelet counts after the first cycle of induction chemotherapy in patients newly diagnosed with acute myeloid leukemia. Methods and results In total, 149 individuals were included in this study. We identified four distinct trajectories using a group-based trajectory model: low- stability group (n = 27, 18.12%), low-level decrease–medium elevation group (n = 42, 28.19%), low-level decrease–high elevation group (n = 60, 40.27%), and high-level decrease–medium elevation group (n = 20, 13.42%). The baseline characteristics of the high-level decrease–medium elevation group included higher platelet count, lower white blood cell count, lower percentage of bone marrow blasts, and lower rates of complete remission after the first cycle of induction chemotherapy. Compared with the low-stability group, the hazard ratios were 0.32 (95% confidence interval, 0.15–0.68) for the low-level decrease–medium elevation group, 0.31 (95% confidence interval, 0.15–0.63) for the low-level decrease–high elevation group, and 0.35 (95% confidence interval, 0.13–0.89) for the high-level decrease–medium elevation group after adjustment for age and gender by Cox proportional hazard regression. Compared with the low-stability group, the hazard ratios were 0.33 (95% confidence interval, 0.14–0.77) for the low-level decrease–medium elevation group and 0.31 (95% confidence interval, 0.14–0.67) for the low-level decrease–high elevation group after adjustment for age, gender, white blood cell count, and bone marrow blasts. These associations persisted after adjusting for age, gender, white blood cell count, bone marrow blasts, and platelet count. Conclusion The dynamic trajectory of platelet counts after the first cycle of induction chemotherapy is a significant predictor of all-cause mortality in patients with acute myeloid leukemia. Timely intervention should be considered for the low-stability group. The low-level decrease–medium elevation and low-level decrease-high elevation groups were independent protective factors for all-cause mortality.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-022-09601-5.pdf
Ending Page	13
Page Count	13
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-022-09601-5
Journal	BMC Cancer
Issue Number	1
Volume Number	22
Language	English
Publisher	BioMed Central
Publisher Date	2022-05-01
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health Acute myeloid leukemia Trajectory Platelet counts All-cause mortality Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Correction: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

Prenatal origin of childhood AML occurs less frequently than in childhood ALL

Targeting CD33 for acute myeloid leukemia therapy

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature

Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients

Similar Documents

Correction: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

Prenatal origin of childhood AML occurs less frequently than in childhood ALL

Targeting CD33 for acute myeloid leukemia therapy

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature

Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients